The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N07 | Other nervous system drugs | |
3
|
N07X | Other nervous system drugs | |
4
|
N07XX | Other nervous system drugs | |
5
|
N07XX27 | Levacetylleucine |
| Active Ingredient |
|---|
|
Levacetylleucine is a modified amino acid that helps break down accumulated lipids in the brain (improves the function of lysosomes and mitochondria). Non-clinical studies demonstrated that levacetylleucine corrects energy metabolism, including improving the production of adenosine triphosphate. It is administered for the treatment of neurological manifestations of Niemann-Pick type C disease (NPC) in adults and children (≥15 kg). |
| Document | Type | Information Source | |
|---|---|---|---|
| AQNEURSA Granules for oral suspension | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.